Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

Ophthalmic Drug Delivery Systems

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Impact of Flap Thickness on Refractive Outcomes and Corneal Biomechanics Following Myopic Femtosecond Laser-Assisted LASIK.

Journal of clinical medicine·2026

Same author

Long-term outcomes of nationwide coordinated neovascular AMD treatment: A study based on Polish national registry.

Acta ophthalmologica·2025

Same author

Twelve-Month Outcomes of Anti-VEGF Therapy for nAMD with Brolucizumab, Aflibercept, and Ranibizumab in the Polish National Registry: A Multicenter Database Study.

Journal of clinical medicine·2025

Same author

Effects of curcumin-liposome formulation on inflammatory cascade activated by oxidative stress in primary human corneal epithelial cells.

Experimental eye research·2025

Same author

Contrast Sensitivity and Stereopsis Outcomes Following LASIK Presbyopia Correction Based on the Corneal Aberration Modulation or Corneal Multifocality Induction Methods: A Systematic Review.

Journal of clinical medicine·2025

Same author

Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks Treatment.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2024

Search research articles

Related Experiment Video

Updated: Jun 7, 2026

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

Future possibilities in glaucoma therapy.

Joanna Wierzbowska¹, Jacek Robaszkiewicz, Małgorzata Figurska

¹Department of Ophthalmology, Military Medical Institute, Warsaw, Poland. joanna.wierzbowska@gmail.com

Medical Science Monitor : International Medical Journal of Experimental and Clinical Research

|October 29, 2010

Summary

Future glaucoma treatments focus on protecting the optic nerve and improving eye health. Strategies include baroprotection, vasoprotection, neuroprotection, and gene therapy to prevent vision loss.

More Related Videos

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Related Experiment Videos

Last Updated: Jun 7, 2026

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Area of Science:

Ophthalmology
Regenerative Medicine
Genetics

Background:

Glaucoma is a leading cause of irreversible optic nerve damage and vision loss.
Current treatments aim to lower intraocular pressure but do not fully prevent disease progression.

Purpose of the Study:

To review emerging therapeutic strategies for glaucoma beyond current standards of care.
To highlight advancements in baroprotection, vasoprotection, neuroprotection, and gene therapy for glaucoma.

Main Methods:

Review of current literature on novel glaucoma treatment modalities.
Analysis of experimental studies investigating new drug classes and therapeutic approaches.

Main Results:

Baroprotection strategies include targeting the actin cytoskeleton and enhancing aqueous humor outflow.
Vasoprotection aims to prevent reperfusion injury, while neuroprotection explores agents like erythropoietin and caspase inhibitors.
Gene therapy targets various ocular tissues for glaucoma treatment, with ongoing research in stem cell therapy and immunotherapy.

Conclusions:

Novel therapeutic avenues offer promise for preserving optic nerve function in glaucoma.
A multi-faceted approach combining different protective and regenerative strategies may be key to future glaucoma management.